Published summary: 2026-03-07
Where the evidence converges
A rigorous crossover trial found CBD had no effect on brain excitability or sedation at either low or high doses, suggesting its anti-epileptic benefits may come from drug interactions rather than direct activity
Moderate evidence · 1 studies
Based on limited number of strong-evidence studies.
Where questions remain
Analysis of 89 daily cannabis users found that 'Willingness to Take Again' better predicted actual cannabis self-administration than the FDA-recommended 'Drug Liking' measure, suggesting regulatory assessment methods may need updating
Moderate evidence · 3 studies
Retrospective analysis of combined datasets with methodological differences between studies. Small sample with predominantly male participants. Daily cannabis users may not represent occasional users.
Crossover trial of 20 adults found CBD co-administration increased THC's subjective high, impairment, and blood concentrations, while caffeine had minimal effects on THC outcomes
Moderate evidence · 3 studies
Small sample (20). Oral administration only, not smoking or vaping. Specific doses may not represent commercial products. Single-session acute effects. Cannot determine chronic co-administration effec
Clinical trial of 12 volunteers found novel sublingual, rectal, and vaporizer cannabis products had faster cannabinoid absorption than approved products like Sativex, with comparable safety
Moderate evidence · 3 studies
Very small sample (n=12). Single-dose design in healthy volunteers. Cannot extrapolate to patients with medical conditions. Crossover design may have period effects. Bioavailability differences may ma
First study characterizing delta-8-THC's drug interaction potential, finding significant inhibition of CYP2C9 and CYP3A4 liver enzymes with clinically relevant predictions
Moderate evidence · 3 studies
In vitro study — actual clinical drug interactions depend on achievable tissue concentrations. Static modeling may over- or underpredict real-world interactions. Individual variation in enzyme activit
Research gaps
- Only 0 randomized controlled trials exist out of 22 studies — most evidence is observational or from reviews.
- Sex-specific differences in this area remain understudied.
- With only 22 studies, this remains an emerging research area where conclusions should be considered preliminary.
- Long-term prospective studies tracking outcomes over 5+ years are largely absent from the literature.
- Research on diverse populations (different ages, ethnicities, and medical backgrounds) remains limited.
Key studies
Mapping How 100+ Cannabis Plant Compounds Interact with the Body
Most cannabis science focuses on just two of 100+ compounds — understanding the full pharmacological landscape could unlock new therapeutic applications and explain the 'entourage effect.'
CBD May Not Have Anti-Seizure Properties On Its Own
If CBD's approved anti-seizure effects are primarily driven by drug interactions with clobazam rather than direct anti-epileptic activity, it fundamentally changes how we understand and prescribe CBD for epilepsy.
New Structural Insights Into How Cannabinoid Receptors Work
Understanding the precise 3D structure of cannabinoid receptors enables drug designers to create medications that target specific receptors more accurately, potentially delivering therapeutic benefits without unwanted psychoactive or immune effects.
THC Kills Pain by Blocking Nerve Signals — Without Involving Cannabis Receptors
NaV1.7 and NaV1.8 are the two most important sodium channels for pain signaling. Finding that THC blocks them directly — like a local anesthetic — provides a completely new framework for developing cannabinoid-based painkillers without psychoactive effects.
'Willingness to Take Again' Better Predicted Cannabis Abuse Potential Than 'Drug Liking'
The FDA uses Drug Liking as the primary measure in abuse potential assessments for new drugs. If this measure is not the best predictor of actual drug-taking behavior for cannabinoids, regulatory evaluations of novel cannabinoid products may need updating.
CBD Increased THC's High and Blood Levels, While Caffeine Had Minimal Impact
Cannabis products premixed with caffeine are increasingly common but have never been studied. The unexpected finding that CBD increases THC's effects and blood levels challenges the common belief that CBD moderates THC's impact.
How the research developed
2020–present
22 studies published. Includes 1 strong-evidence studies.
How this summary was assembled
This consensus synthesizes 22 peer-reviewed studies: 4 reviews (18%), 18 other study types (82%). Studies span from the earliest available research through 2025. Evidence strength ratings reflect study design, sample size, and replication across multiple research groups.
These counts describe the source summary at publication. They may differ from the current library.